Bio-Rad Laboratories-A
BIO高于价值2 位超级投资者持有。
SEC 10-K · 基本面
生意质量
截至 2025-12-31估值口径：截至 2026-06-30 的滚动十二个月（最新 10-K 叠加未审计 10-Q）。
- 营收增速
- +0.7%
- 净利率
- 29.4%
- ROE
- 10.2%
- FCF 利润率
- 14.5%
估值 · 价值带
高于合理价值
$262 价值估计
Bio-Rad Laboratories-A（BIO）：一项保守的盈利能力估计，$262 / 股；今日价格高于它（价格 $389 截至 2026-08-26）。
零增长下行 $262
价格截至 2026-08-26 · yahoo.
方法与数字
保守内在价值带（零增长底到增速封顶的 DCF）加一道有形资产地板 — 非投资建议、非买卖信号、亦非目标价。
· Greenwald 零增长 $262.30 · 零增长基准 $262.30 · 重置 $262.30
护城河 低于资产基础.
Graham earnings-power value (normalized NOPAT)$13.87 – $19.32 / 股
Normalized NOPAT = average operating margin over the years shown × latest-year revenue × (1 − normalized tax); then + D&A − maintenance capex (write A). Unlevered (pre-interest, attributable to all capital). Capitalized at the 9–11% rate band (read as a WACC proxy). Enterprise → equity bridge applied: + cash − total debt.
年份：TTM 2026-06-30, 2024, 2023, 2022, 2021
v1 简化：Maintenance capex (degraded) deducted in full cash (write A): EPV = (NOPAT + D&A − maintenance capex) / WACC; no tax shield on the capex term. Maintenance-capex methods diverge by 83% (> 50%); estimate is degraded. Share-based compensation is left as a real expense (not added back). Operating margin is below its multi-year average (cyclical/declining): normalized margin capped at the latest year — no peak-margin capitalization (audit #2).
Buffett owner-earnings value
Normalized owner earnings are non-positive over the years shown; earnings power cannot be capitalized.
Owner earnings = average net income + average D&A − maintenance capex (zero-growth floor; no ΔNWC). Levered (starts from net income, already after interest — an equity-holder stream). Capitalized at the 9–11% rate band (read as a cost-of-equity proxy). No enterprise→equity bridge: the capitalized result is already equity value (subtracting debt would double-count interest).
年份：TTM 2026-06-30, 2024, 2023, 2022, 2021
v1 简化：Owner earnings = net income + D&A − maintenance capex (degraded); the working-capital change is excluded (maintenance ΔNWC ≈ 0; growth ΔNWC is carried in growth value, not double-counted). Maintenance-capex methods diverge by 83% (> 50%); estimate is degraded. One-time items are not separately normalized (multi-year averaging smooths them partially). Share-based compensation is left as a real expense (not added back); see the SBC/OE disclosure. Capitalized at the 9–11% band as a cost-of-equity proxy; no leverage premium applied. Net debt or owner earnings is unavailable, so no adjustment is made.
重置价值 = 有形净资产 $6.44B + 资本化研发 $593.59M（FY 2026, 2024, 2023, 2022） = $262.30 / 股. Reproduction value = tangible net assets (equity − goodwill − intangibles) + capitalized R&D (5y straight-line), ÷ diluted shares.
护城河读数：Franchise test compares earnings power (EPV) against reproduction value on both AV_conservative (tangible + capitalized R&D) and AV_reproduction (conservative + acquired-reset proxy). Both must clear the franchise multiple for a moat signal; near it, a commodity; below it, value destruction. A directional reading, not a verdict.
增长价值被闸至零 — 无护城河或 ROIIC ≤ WACC，故不计入增长价值。
窗口 TTM 2026-06-30, FY 2024, 2023, 2022, 2021 · 贴现带 9%–11% · 正常化税率 21% (Average effective tax rate over 5 year(s), capped at the statutory 21%.) · 股数 diluted.
估值口径：截至 2026-06-30 的滚动十二个月（最新 10-K 叠加未审计 10-Q）。
内在价值怎么读SEC 13F · 持有人
持有该证券的超级投资者
2 位持有 · 合计 $357.8M · 本季 +0 新建 / -2 清仓
- 市值$239.8M权重（上季→本季）2.5% → 2.4% ▼
- 市值$118.0M权重（上季→本季）1.6% → 1.5% ▼
SEC 13F · 说明
文字说明
文字说明
Bio-Rad Laboratories-A（BIO）被 Compounder 追踪的 2 位超级投资者持有，合计申报市值 $357.8M。仓位最大的是 John Rogers，占其组合 2.4%。
按市值，其他主要持有人包括 Steven Romick（占其组合 1.5%）。
最近一个季度，追踪范围内有 0 位新建 BIO 仓位，1 位加仓，1 位减仓，2 位清仓。
以上持有人数与市值来自最新的 SEC Form 13F 申报，截至 2026-06-30 季度。来源：SEC EDGAR。13F 仅涵盖美股多头持仓，且可能滞后实际组合最多 45 天，因此这是已披露的多头持有情况，并非完整全貌。
SEC 13F · 共持信号
他们还共同持有
持有 Bio-Rad Laboratories-A（BIO）的这些人还共同重仓 →
BIO 现价不低于保守价值带。 看当前击球区股票
数据来源· SEC EDGAR 13F 截至 2026-06-30 · 2026-08-14 提交
仅供教育与信息参考，不构成投资建议。13F 持仓为机构自行申报，可能滞后最多 45 天。
订阅更新
新一季 13F 异动与估值更新，发到你的邮箱。